Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 5 Average cost-effectiveness (CE) and incremental cost-effectiveness (ICE) ratio of assessed antipsychotics versus haloperidol (€, 2009)

From: Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

Strategy

Average CE ratio (€/QALY)

ICE ratio (€/QALY gained) versus haloperidol

Amisulpride

5,792

91,584

Aripiprazole

6,386

94,558

Haloperidol

4,593

NA

Olanzapine

5,208

23,621

Paliperidone ER

4,043

Dominant

Risperidone

4,353

Dominant

  1. Dominant: strategy with higher effectiveness (QALYs) and lower cost